326 related articles for article (PubMed ID: 35844536)
1. Exploration of Novel Immunological Terms in Lung Cancer With Large Populations: Implications for Immunotherapy.
Yao Y; Wang J; Yang F; Gao W
Front Immunol; 2022; 13():924498. PubMed ID: 35844536
[TBL] [Abstract][Full Text] [Related]
2. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
Front Immunol; 2021; 12():693062. PubMed ID: 34497605
[TBL] [Abstract][Full Text] [Related]
3. Prognostic characterization of immune molecular subtypes in non-small cell lung cancer to immunotherapy.
Li C; Pan J; Luo J; Chen X
BMC Pulm Med; 2021 Nov; 21(1):389. PubMed ID: 34844602
[TBL] [Abstract][Full Text] [Related]
4. Construction and validation of immune-related LncRNAs classifier to predict prognosis and immunotherapy response in laryngeal squamous cell carcinoma.
Wang X; Pan Y; Ou Y; Duan T; Zou Y; Zhou X
World J Surg Oncol; 2022 May; 20(1):164. PubMed ID: 35606755
[TBL] [Abstract][Full Text] [Related]
5. Identification and Validation of a Tumor Microenvironment-Related Gene Signature for Prognostic Prediction in Advanced-Stage Non-Small-Cell Lung Cancer.
Zhang X; Shi X; Zhao H; Jia X; Yang Y
Biomed Res Int; 2021; 2021():8864436. PubMed ID: 33860055
[TBL] [Abstract][Full Text] [Related]
6. Construction of a B cell-related gene pairs signature for predicting prognosis and immunotherapeutic response in non-small cell lung cancer.
Li X; Wang R; Wang S; Wang L; Yu J
Front Immunol; 2022; 13():989968. PubMed ID: 36389757
[TBL] [Abstract][Full Text] [Related]
7. Immune Microenvironment and Response in Prostate Cancer Using Large Population Cohorts.
Ren X; Chen X; Zhang X; Jiang S; Zhang T; Li G; Lu Z; Zhang D; Wang S; Qin C
Front Immunol; 2021; 12():686809. PubMed ID: 34777331
[TBL] [Abstract][Full Text] [Related]
8. Characterization of stemness features and construction of a stemness subtype classifier to predict survival and treatment responses in lung squamous cell carcinoma.
Lai J; Lin X; Zheng H; Xie B; Fu D
BMC Cancer; 2023 Jun; 23(1):525. PubMed ID: 37291533
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analyses of a CD8
Chen L; Weng Y; Cui X; Li Q; Peng M; Song Q
BMC Bioinformatics; 2023 Jun; 24(1):238. PubMed ID: 37280525
[TBL] [Abstract][Full Text] [Related]
10. Deciphering a cell death-associated signature for predicting prognosis and response to immunotherapy in lung squamous cell carcinoma.
Mao G; Yang D; Liu B; Zhang Y; Ma S; Dai S; Wang G; Tang W; Lu H; Cai S; Zhu J; Yang H
Respir Res; 2023 Jul; 24(1):176. PubMed ID: 37415224
[TBL] [Abstract][Full Text] [Related]
11.
Zhang N; Shen J; Gou L; Cao M; Ding W; Luo P; Zhang J
Bioengineered; 2022 May; 13(5):11577-11592. PubMed ID: 35531878
[TBL] [Abstract][Full Text] [Related]
12. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
Li B; Cui Y; Diehn M; Li R
JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
[TBL] [Abstract][Full Text] [Related]
13. Machine learning-identified stemness features and constructed stemness-related subtype with prognosis, chemotherapy, and immunotherapy responses for non-small cell lung cancer patients.
Liu M; Zhou R; Zou W; Yang Z; Li Q; Chen Z; Jiang L; Zhang J
Stem Cell Res Ther; 2023 Sep; 14(1):238. PubMed ID: 37674202
[TBL] [Abstract][Full Text] [Related]
14. A 13-gene signature to predict the prognosis and immunotherapy responses of lung squamous cell carcinoma.
Yang Q; Gong H; Liu J; Ye M; Zou W; Li H
Sci Rep; 2022 Aug; 12(1):13646. PubMed ID: 35953696
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory response signature score model for predicting immunotherapy response and pan-cancer prognosis.
Chen S; Huang M; Zhang L; Huang Q; Wang Y; Liang Y
Comput Struct Biotechnol J; 2024 Dec; 23():369-383. PubMed ID: 38226313
[TBL] [Abstract][Full Text] [Related]
16. A Novel Immune-Related Seventeen-Gene Signature for Predicting Early Stage Lung Squamous Cell Carcinoma Prognosis.
Fan T; Lu Z; Liu Y; Wang L; Tian H; Zheng Y; Zheng B; Xue L; Tan F; Xue Q; Gao S; Li C; He J
Front Immunol; 2021; 12():665407. PubMed ID: 34177903
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis of the immunological implication and prognostic value of CXCR4 in non-small cell lung cancer.
Guo W; Huai Q; Zhou B; Guo L; Sun L; Xue X; Tan F; Xue Q; Gao S; He J
Cancer Immunol Immunother; 2023 Apr; 72(4):1029-1045. PubMed ID: 36308553
[TBL] [Abstract][Full Text] [Related]
18. A signature of tumor immune microenvironment genes associated with the prognosis of non‑small cell lung cancer.
Li J; Li X; Zhang C; Zhang C; Wang H
Oncol Rep; 2020 Mar; 43(3):795-806. PubMed ID: 32020214
[TBL] [Abstract][Full Text] [Related]
19. [Cuproptosis-related immune gene signature predicts clinical benefits from anti-PD-1/PD-L1 therapy in non-small-cell lung cancer.
Luo L; Li A; Fu S; Du W; He LN; Zhang X; Wang Y; Zhou Y; Yunpeng Y; Li Z; Hong S
Immunol Res; 2023 Apr; 71(2):213-228. PubMed ID: 36434349
[TBL] [Abstract][Full Text] [Related]
20. Identification of a risk score model based on tertiary lymphoid structure-related genes for predicting immunotherapy efficacy in non-small cell lung cancer.
Mei SQ; Liu JQ; Huang ZJ; Luo WC; Peng YL; Chen ZH; Deng Y; Xu CR; Zhou Q
Thorac Cancer; 2024 May; 15(14):1119-1131. PubMed ID: 38558529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
